Dr. Angelika Vlachou
Partner
About me
| Team | Berlin Team, Investment comittee, Life Sciences & Chemistry, Partner |
| at HTGF since | 2021 |
CV
Dr. Angelika Vlachou has been investing venture capital in biotech, pharma and life science start-ups for over 10 years. Over the course of her career, she has managed many transactions ranging from seed-stage venture capital and growth financing to licensing agreements, trade sale transactions and IPOs. Her expertise is also based on her virology-molecular biology research experience. One of her strengths is to combine scientific innovation with commercial potential. She is a valued sparring partner for founders, investors and stakeholders. With a doctorate in biology, she started her professional career in investment banking.
My success stories in the HTGF portfolio
SRTD biotech was founded in Jülich by Dr Bernd Hoffmann and Dr Heribert Bohlen. The aim of the biotech start-up is to develop highly efficient RNA-based drugs based on a …
to SRTD biotech
smartbax is developing a new generation of antibiotics to address the increasing spread of multi-drug resistant bacteria. Their team of experts is advancing a complementary pipeline of small molecules against …
to smartbax
Kupando is a pioneering biopharmaceutical company developing TLR 4/7 agonists that stimulate innate immunity for use in oncology and infectious diseases. The Company uses its small molecule-based drug candidates to …
to Kupando
faCellitate develops patented polymeric surface coatings for plastic and glassware enabling 3-dimensional cell culture, amongst other uses. Initially, the technology was developed at the BASF research department for polymers. The …
to faCellitate
Lindis Blood Care is developing a medical device to be used in oncology for the operation of tumours in order to open up the possibility of self-blood administration of blood …
to Lindis Blood Care
mediaire develops AI-powered diagnostic solutions for MRI imaging, focusing on the seamless integration of AI into clinical workflows to enhance radiologists’ efficiency and diagnostic accuracy. The company’s AI solutions, including …
to mediaire
miRdetect is a biotechnology company founded in 2016, with the aim to revolutionise cancer diagnostics. The focus is on development, production and distribution of in-vitro diagnostics based on molecular diagnostic …
to miRdetect
Guided to exit
Exit
adivo is a biotech company generating therapeutic antibodies for companion animals, addressing the medical needs in dogs, with an upside potential for a future in care for other species. Antibody …
to adivo
Recent posts
zum Artikel
smartbax announces a €4.7 M Pre-Series A round to advance novel antibiotic compound through preclinical stage
zum Artikel
Lindis Blood Care Announces Successful Financing for its Tumor-Cell-Removal Medical Device, CATUVAB®
zum Artikel
SRTD biotech secures seed financing: Side-effect freeRNA therapeutics active only in diseased cells
zum Artikel